Kee Song Bio-Technology Holdings Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 588.38 million compared to TWD 548.2 million a year ago. Net loss was TWD 47.7 million compared to TWD 9.04 million a year ago. Basic loss per share from continuing operations was TWD 1.29 compared to TWD 0.24 a year ago. Diluted loss per share from continuing operations was TWD 1.29 compared to TWD 0.24 a year ago.
For the nine months, sales was TWD 1,845.99 million compared to TWD 1,688.99 million a year ago. Net income was TWD 18.98 million compared to TWD 32.01 million a year ago. Basic earnings per share from continuing operations was TWD 0.52 compared to TWD 0.87 a year ago. Diluted earnings per share from continuing operations was TWD 0.52 compared to TWD 0.87 a year ago.